Scilex Holding (SCLX) Capital Expenditures (2022 - 2026)

Scilex Holding (SCLX) posted quarterly Capital Expenditures of $605000.0 for Q1 2026, up 20066.67% quarter-over-quarter from $3000.0 in Q4 2025.

Scilex Holding (SCLX) Capital Expenditures (2022 - 2026) Analysis & Trends

Scilex Holding's Capital Expenditures history runs 5 years deep, the most recent figure standing at $605000.0 for Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to $605000.0; the TTM figure through Mar 2026 stood at $608000.0 (up 2126.67% YoY), while the FY2025 annual figure was $3000.0, changed N/A from the prior year.
Capital Expenditures for Q1 2026 stood at $605000.0, up from $3000.0 in the prior quarter.
The five-year high for Capital Expenditures was $1.0 million in Q2 2023, with the low at -$997000.0 in Q1 2023.
The 5-year median for Capital Expenditures is -$13500.0 (2024), against an average of -$59700.0.
The sharpest annual moves came in 2023 and 2025: Capital Expenditures slumped 245.71% in 2023, then surged 110.0% in 2025.
Scilex Holding's Capital Expenditures stood at $35000.0 in 2022, then plunged by 245.71% to -$51000.0 in 2023, then soared by 41.18% to -$30000.0 in 2024, then soared by 110.0% to $3000.0 in 2025, then jumped by 20066.67% to $605000.0 in 2026.
Business Quant data shows SCLX's Capital Expenditures at $605000.0 in Q1 2026, $3000.0 in Q4 2025, and -$30000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	1.32 Bn
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	322.00 Mn
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	893.00 Mn
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	321.00 Mn
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	1.86 Bn
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	513.00 Mn
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	140.00 Mn
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	533.00 Mn
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	-440.07 Mn
10	Scilex Holding	39.35 Mn	-73.44 Mn	3.97 Mn	389,000.00

Download Data